1 November 2018 in Reproductive BioMedicine Online
KCKaterina Chatzimeletiou
+3
15 June 2024 in Middle East Fertility Society Journal
MAMahmoud Ahmad Abdel-Mawjud
Mahmoud Ahmad Abdel-Mawjud
Background: To compare two types of intrauterine devices, namely Cu T380A IUD and Multiload 375 IUD, inserted immediately post-placental during cesarean section, with regard to expulsion rates and side effects. Methods: A randomized comparative clinical trial was carried out over 200 patients with 100 patients in each group. Transabdominal ultrasonography (US) was done on all patients before discharge to ensure the adequate position of the IUD in addition to casco speculum examination to assess the IUD threads, and then women were requested to attend a follow-up appointment at 6 weeks after delivery; gynecological examinations in addition to transvaginal sonography were done to measure the top-fundal distance that reflects the position of the IUD. The participants were instructed to report the pattern of bleeding during the puerperium, fever, or vaginal discharge. Results: The ultrasonographic assessment of IUD position before patient discharge (1st assessment) revealed that 18% of Cu T380A IUD users were displaced in comparison to 24% of Multiload 375 IUD, and such difference between both groups was not statistically significant (P = 0.3); furthermore, the ultrasonographic assessment of IUD position after 6 weeks (2nd assessment) revealed that 19% of Cu T380A IUD users were displaced in comparison to 30% of Multiload 375 IUD, and such difference between both groups was statistically significant (P = 0.047). In addition, none of the included patients in both groups suffered from fever after IUD insertion. Conclusion: The present study demonstrated that post-placental insertion of Multiload 375 IUCD results in significantly higher displacement compared to post-placental insertion of Cu T380A IUCD, as well as significantly more bleeding problems with Cu T380A IUCD as compared with Multiload 375 IUCD. Trial registration: The study was registered prospectively on clinical trial.gov with trial registeration number NCT05624411 (Registered 22-October-2022, https://clinicaltrials.gov/study/NCT05624411).
1 June 2025 in Research in Oncology
NENoha E. D. Hassab El-Naby
Noha E. D. Hassab El-Naby
Background: Ovarian neoplasm refers to any tumor that originates primarily in the ovary. Epithelial ovarian neoplasms are the most common type of ovarian tumor and are classified based on their histogenetic and immunophenotypic features. However, treatment modalities based on this classification have shown limited improvements in patient outcomes. Engrailed (EN)-2 was first identified as a regulator of embryonic neural development and later found to be expressed in various non-neural epithelial tumors. Aim: This study aimed to investigate the potential role of the EN-2 gene in epithelial ovarian tumors by comparing the expression of EN-2 protein in functional ovarian lesions and ovarian epithelial neoplasms. It also aimed to correlate EN-2 expression levels with factors such as patient age, tumor size, and carcinoma grade. Methods: Archived formalin-fixed, paraffin-embedded ovarian tissue blocks from 47 women who underwent oophorectomies for various gynecological indications were examined. Two tissue sections were obtained from each block: one was stained with Hematoxylin and Eosin, and the other was immunohistochemically stained with an anti-human EN-2 antibody. Results: EN-2 was overexpressed in malignant ovarian neoplasms compared to benign tumors and non-neoplastic lesions (p < 0.0001). The expression of EN-2 was significantly associated with older patient age (p=0.003) and larger tumor size (p < 0.0001). Conclusion: EN-2 is aberrantly expressed in epithelial ovarian neoplasms, with increased expression observed in malignant tumors and larger tumor sizes, suggesting its potential as a biomarker for tumor progression in ovarian carcinoma.
10 June 2020 in Sohag Medical Journal
COVID-19, the disease caused by a new coronavirus, has quickly raised the world concern by spreading globally at an accelerated rate and is now a pandemic, according to the World Health Organization. But limited data are available for pregnant women with COVID-19 infection. The pregnant women present a unique challenge during the COVID-19 pandemic and several questions remain about pregnant women and their newborns. whether they will develop distinct symptoms from non-pregnant adults and whether COVID-19 could spread vertically pose risks to the fetus and neonate. Information on adverse pregnancy outcomes in pregnant women with COVID-19 is lacking. Previous reports on pregnant women with SARS and MERS show higher case fatality rate, while, COVID-19 appears less-lethal Compared with SARS and MERS,In this study we aim to highlight COVID-19 infection during pregnancy, bringing together the various factors integral to the understanding of clinical manifestations, diagnostic challenge and susceptibleness with the virus, intrauterine infection and maternal-fetal complications, therapeutic controversies,
8 May 2026 in European Journal of Obstetrics & Gynecology and Reproductive Biology